[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lactose-malabsorption\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lactose-malabsorption":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100575543","proper-dietary-management-follow-up-and-lactase-enzyme-supplementation-for-lactose-intolerance-100575543",false,"NCT06773650","Proper Dietary Management, Follow-up, and Lactase Enzyme Supplementation for Lactose Intolerance","Lactose Intolerance: a Guide to Proper Dietary Management, Follow-up, and Lactase Enzyme Supplementation","Inclusion Criteria:\n\n* Subjects must be adults (≥18 years of age)\n* Willingness to complete the online survey\n\nExclusion Criteria:\n\n* Subjects \\\u003C18 years of age\n* Subjects not available to answer the online survey","ALL","18 Years",{"count":19,"type":20},385,"ESTIMATED","OBSERVATIONAL","Lactose intolerance (LI) is considered the clinical syndrome caused by lactose malabsorption (LM).\n\nIt is possible to identify four causes of lactase deficiency defining four different types of LM: primary (genetic), secondary (acquired), congenital (alactasia), and developmental (in premature infants, so reversible).\n\nThe aim of this protocol is to investigate through an anonymous online survey the knowledge of the Italian population on clinical, pathophysiological, diagnostic and therapeutic issues of lactose intolerance. Data collected will be divulgated through a publication for both people with IL and nutritionists, enriched with tables and flow charts, to improve the knowledge on lactose intolerance and to support people suffering from this condition. The results of this survey will guide subjects suspected of suffering from lactose intolerance towards a correct diagnosis and a better management.",[24,25,26],"Lactose Intolerant","Lactose Malabsorption","Lactose Intolerance","RECRUITING","2025-01-09",{"date":30,"type":31},"2025-01-14","ACTUAL",{"date":33,"type":31},"2025-01-08",{"date":35,"type":20},"2026-01",{"name":37,"class":38},"European Institute of Oncology","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},"100446998","the-role-of-irritable-bowel-syndrome-in-lactose-intolerance-lion-100446998","NCT05100719","The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)","The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION Trial): Protocol of a Multicentre Randomized Controlled Clinical Trial","LION","Inclusion Criteria:\n\n* age 18-80 years\n* patients diagnosed with irritable bowel syndrome based on the ROME IV. criteria\n* positive LHBT (lactose H2 breath test) and LTT (lactose tolerance test) results\n* negative abdominal ultrasound\u002FCAT scan\u002FMRI results within one year\n* signed the informed consent\n\nExclusion Criteria:\n\n* organic gastroenterological disorders which can explain symptoms (e.g. positive serological screening: anti-gliadin IgG \u002F IgA, anti-tissue transglutaminase IgG \u002F IgA, high level of fecal calprotectin tested by endoscopy or positive colonoscopy for IBD, currently active diverticulitis\n* Alarm symptoms: fever (\\> 38 Co), anaemia (Hgb \\\u003C 120 g\u002Fl), unintended weight loss (\\> 4.5 kg \u002F 3 months), gastrointestinal bleeding (hematemesis, hematochesia, melena)\n* cardiac failure (NYHA III-IV)\n* liver cirrhosis (Child-Pugh C)\n* active malignancy\n* major abdominal surgery in the history\n* pregnant or breastfeeding women\n* any circumstances which can lead to false results of LHBT and LTT: cigarette smoking or physical exercise within 2 hours before the test, ingestion of dietary fibers on the evening before the test, recent use of antibiotics, lung disease, baseline H2 concentration in the exhaled air is higher than 20 ppm, not properly treated diabetes mellitus, following lactose restricted or another special diet within 1 week prior to study enrolment (ingestion of less than 12 g lactose - less than 250 ml milk - per day)\n* small intestinal bacterial overgrowth (SIBO): if there is a rapid increase of H2 level in the exhaled air (≥20 ppm above baseline within 90 minutes), SIBO is suspected and antibiotic therapy will be started (peroral rifaximin for 5 days) after negative Helicobacter pylori serology. After this procedure, lactulose H2 breath test will be performed to exclude SIBO (≥20 ppm H2 rise only after 90 min). In case of negative lactulose H2 breath test, another LHBT will be carried out\n* slow oro-cecal transit: clinical signs and typical findings on the tests (the LHBT is normal, but the increase of blood glucose level is less than 1.1 mmol\u002Fl and\u002For no H2 rise during lactulose H2 breath test)\n* milk allergy (positive IgE test)","80 Years",{"count":50,"type":20},200,"INTERVENTIONAL",[53],"NA","Irritable bowel syndrome (IBS) is a functional gastrointestinal disease. There is no well-defined pharmacological treatment. This clinical trial is a prospective, double-blind, two-armed randomized controlled, single-center trial. It is created to examine the role of IBS in patients with lactose intolerance. IBS patients undergo lactose H2 breath test (LHBT) and lactose tolerance test (LTT). Those with positive LTT and LHBT will be randomized into two groups: alverine-citrate + simethicone and lactase group (1) or alverin-citrate + simethicone with the placebo group (2). The goal of this study is to compare the lactase enzyme with placebo in IBS patients with lactose intolerance.",[56,26,25],"Irritable Bowel Syndrome",[58,59,60,61,62,63,64],"irritable bowel syndrome","lactose intolerance","lactose malabsorption","lactase","simethicone","alverine-citrate","placebo","NOT_YET_RECRUITING","2021-10-19",{"date":68,"type":31},"2021-10-29",{"date":70,"type":20},"2022-09",{"date":72,"type":20},"2026-12",{"name":74,"class":38},"University of Pecs"]